Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: August 2010

Levetiracetam

Related content

Powered by UNSILO
Suggested reading
Ben-Menachem, E, Falter, U; for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276–1283.
Berkovic, SF, Knowlton, RC, Leroy, RF, Schiemann, J, Falter, U; Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69: 1751–1760.
Brodie, MJ, Perucca, E, Ryvlin, P, Ben-Menachem, E, Meencke, HJ; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402–408.
Gallagher, MJ, Eisenman, LN, Brown, KM, Erbayat-Altay, E, Hecimovic, H, Fessler, AJ, Attarian, HP, Gilliam, FG. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia 2004; 45: 90–91.
Johannessen, Landmark C, Patsalos, PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119–140.
Kossoff, EH, Bergey, GK, Freeman, JM, Vining, EP. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611–1613.
Patsalos, PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
Patsalos, PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology and Therapeutics 2000; 85: 77–85.
Patsalos, PN. Clinical pharmacokinetics of levetiracetam. Clinical Pharmacokinetics 2004; 43: 707–724.
Patsalos, PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Reviews in Contemporary Pharmacotherapy 2004; 13: 1–168.
Patsalos, PN, Ghattura, S, Ratnaraj, N, Sander, JW. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia 2006; 47: 1818–1821.
Pellock, JM, Glauser, TA, Bebin, EM, Fountain, NB, Ritter, FJ, Coupez, RM, Shileds, WD. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42: 1574–1579.
Rocamora, R, Wagner, K, Schulze-Bonhage, A. Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. Seizure 2006; 15: 428–433.
Shorvon, SD, Löwenthal, A, Janz, D, Bielen, E, Loiseau, P; for the European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179–1186.
Specchio, LM, Gambardella, A, Giallonardo, AT, Michelucci, R, Specchio, N, Boero, G, Neve, A. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Research 2006; 71: 32–39.